SC
Stempoint Capital Portfolio holdings
AUM
$520M
1-Year Est. Return
281.95%
This Fund
S&P 500
1 Year Est. Return
+281.95%
AUM
$520M
AUM Growth
-$62.4M
(-11%)
Holding
112
Top Buys
| 1 | +$22.2M | |
| 2 | +$17.4M | |
| 3 | +$14.3M | |
| 4 |
CG Oncology
CGON
|
+$11.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$10.9M |
Top Sells
| 1 | +$28.9M | |
| 2 | +$21.7M | |
| 3 | +$21.3M | |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$17.6M |
| 5 |
Roivant Sciences
ROIV
|
+$14.9M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Nektar Therapeutics
NKTR
$1.98B
| – | – |
-178,274
|
|
||
102
Ocular Therapeutix
OCUL
$1.82B
| – | – |
-522,693
|
|
||
103
Olema Pharmaceuticals
OLMA
$934M
| – | – |
0
|
|
||
104
Palisade Bio
PALI
$323M
| – | – |
-4,192,375
|
|
||
105
Quince Therapeutics
QNCX
$20.5M
| – | – |
-73,926
|
|
||
106
Invesco QQQ Trust
QQQ
$496B
| – | – |
0
|
|
||
107
Repligen
RGEN
$6.83B
| – | – |
-15,707
|
|
||
108
Rhythm Pharmaceuticals
RYTM
$5.78B
| – | – |
-58,915
|
|
||
109
State Street SPDR S&P Biotech ETF
XBI
$7.78B
| – | – |
0
|
|
||
110
Xilio Therapeutics
XLO
$53.9M
| – | – |
-145,002
|
|
||
|
BBOT
111
BridgeBio Oncology
BBOT
$662M
| – | – |
-86,517
|
|
||
|
MAZE
112
Maze Therapeutics
MAZE
$1.34B
| – | – |
-125,877
|
|